UY28049A1 - Derivados de (6,7-dihidro-5h-imidazo(1,2-a) imidazol-3-sulfonilamino)-propionamida - Google Patents

Derivados de (6,7-dihidro-5h-imidazo(1,2-a) imidazol-3-sulfonilamino)-propionamida

Info

Publication number
UY28049A1
UY28049A1 UY28049A UY28049A UY28049A1 UY 28049 A1 UY28049 A1 UY 28049A1 UY 28049 A UY28049 A UY 28049A UY 28049 A UY28049 A UY 28049A UY 28049 A1 UY28049 A1 UY 28049A1
Authority
UY
Uruguay
Prior art keywords
propionamide
imidazo
imidazol
derivatives
sulphonylamine
Prior art date
Application number
UY28049A
Other languages
English (en)
Inventor
Terence Alfred Kelly
Jin Mi Kim
Rene M Lemieux
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of UY28049A1 publication Critical patent/UY28049A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Derivados de (6,7-dihidro-5H-imidazo(1,2-a) imidazol-3-sulfonilamino)-propionamida que muestran buen efecto inhibidor sobre la interacción de CAM y leucointegrinas y son así útiles en el tratamiento de enfermedades inflamatorias.
UY28049A 2002-10-30 2003-10-28 Derivados de (6,7-dihidro-5h-imidazo(1,2-a) imidazol-3-sulfonilamino)-propionamida UY28049A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42244602P 2002-10-30 2002-10-30

Publications (1)

Publication Number Publication Date
UY28049A1 true UY28049A1 (es) 2004-05-31

Family

ID=32312506

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28049A UY28049A1 (es) 2002-10-30 2003-10-28 Derivados de (6,7-dihidro-5h-imidazo(1,2-a) imidazol-3-sulfonilamino)-propionamida

Country Status (32)

Country Link
US (4) US6844360B2 (es)
EP (1) EP1560830B1 (es)
JP (1) JP4366477B2 (es)
KR (1) KR20050067426A (es)
CN (1) CN1708500A (es)
AR (1) AR041854A1 (es)
AT (1) ATE343582T1 (es)
AU (1) AU2003284938A1 (es)
BR (1) BR0315836A (es)
CA (1) CA2504219A1 (es)
CO (1) CO5690604A2 (es)
CY (1) CY1106258T1 (es)
DE (1) DE60309344T2 (es)
DK (1) DK1560830T3 (es)
EA (1) EA008443B1 (es)
EC (1) ECSP055823A (es)
ES (1) ES2276134T3 (es)
HR (1) HRP20050387A2 (es)
MX (1) MXPA05004480A (es)
MY (1) MY136822A (es)
NO (1) NO20052579L (es)
NZ (1) NZ540269A (es)
PE (1) PE20040782A1 (es)
PL (1) PL375709A1 (es)
PT (1) PT1560830E (es)
RS (1) RS20050327A (es)
SI (1) SI1560830T1 (es)
TW (1) TW200424204A (es)
UA (1) UA80160C2 (es)
UY (1) UY28049A1 (es)
WO (1) WO2004041827A2 (es)
ZA (1) ZA200502701B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
US6852748B1 (en) * 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
US6844360B2 (en) * 2002-10-30 2005-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide
EP1712553A3 (en) * 2002-10-30 2006-11-02 Boehringer Ingelheim Pharmaceuticals, Inc. Derivates of [6, 7-dihydro - 5H - imidazo[1,2- alpha]imidazole-3-sulfonylamino]-propionamide and their use as inhibitors upon the interaction of CAMS and leukointegrins
US8699508B2 (en) * 2003-12-18 2014-04-15 Intel Corporation Response scheduling for multiple receivers
WO2006014828A1 (en) * 2004-07-27 2006-02-09 Boehringer Ingelheim International, Gmbh Synthesis of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonic acid amides
JP2008536834A (ja) * 2005-04-06 2008-09-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ［６，７−ジヒドロ−５Ｈイミダゾ［１，２−α］イミダゾール−３−スルホニル］−アゼテジン−カルボン酸、エステル及びアミドの誘導体及び抗炎症薬としてのそれらの使用
BRPI0610354A2 (pt) * 2005-05-19 2010-06-15 Boehringer Ingelheim Internac derivados de ácido 6,7-diidro-5h-imidazo[1,2-a]imidazol-3-slfÈnico, bem como composição farmacêutica e uso dos mesmos
CA2636455A1 (en) * 2006-01-20 2007-07-26 Boehringer Ingelheim International Gmbh Process for the preparation of 6,7-dihydro-5h-imidazo[1,2-a]imidazole-3-sulfonic acid amides and intermediates used therein
PL2225238T3 (pl) * 2007-11-29 2015-03-31 Boehringer Ingelheim Int Pochodne amidów kwasu 6,7-dihydro-5H-imidazo[1,2-a]imidazolo-3-karboksylowego
EP2445909B1 (en) * 2009-06-02 2013-11-13 Boehringer Ingelheim International GmbH DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
WO2010141330A1 (en) 2009-06-02 2010-12-09 Boehringer Ingelheim International Gmbh DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
WO2021217041A1 (en) * 2020-04-24 2021-10-28 Immvention Therapeutix N-substituted alpha-amino and alpha-hydroxy carboxamide derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355664B1 (en) 1997-03-03 2002-03-12 Boehringer Ingelheim Pharmaceuticals, Inc. Phenylpyrrolidines, phenylimidazolidines, 3-phenyl-1,3-oxizolidines and 3-phenyl-1,3-thiazolidines and their use in the treatment of inflammatory disease
DK0966447T3 (da) 1997-03-03 2003-06-23 Boehringer Ingelheim Pharma Anvendelige små molekyler til behandling af betændelsessygdomme
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
JP2004505978A (ja) * 2000-08-09 2004-02-26 ベーリンガー　インゲルハイム　ファーマシューティカルズ　インコーポレイテッド （Ｒ）−３−（４−ブロモベンジル）−１−（３，５−ジクロロフェニル）−５−ヨード−３−メチル−１−Ｈ−イミダゾ［１，２−ａ］イミダゾール−２−オンの合成
US6852748B1 (en) * 2002-10-30 2005-02-08 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide
US6844360B2 (en) * 2002-10-30 2005-01-18 Boehringer Ingelheim Pharmaceuticals, Inc. Derivatives of [6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonylamino]-propionamide

Also Published As

Publication number Publication date
US20040127534A1 (en) 2004-07-01
AR041854A1 (es) 2005-06-01
NO20052579L (no) 2005-05-27
HRP20050387A2 (en) 2006-10-31
AU2003284938A1 (en) 2004-06-07
KR20050067426A (ko) 2005-07-01
US7345074B2 (en) 2008-03-18
CO5690604A2 (es) 2006-10-31
EA008443B1 (ru) 2007-06-29
WO2004041827A3 (en) 2004-07-15
PL375709A1 (en) 2005-12-12
EP1560830A2 (en) 2005-08-10
ECSP055823A (es) 2005-08-11
US7304067B2 (en) 2007-12-04
US6844360B2 (en) 2005-01-18
CY1106258T1 (el) 2011-06-08
PE20040782A1 (es) 2004-12-16
NZ540269A (en) 2007-05-31
WO2004041827A2 (en) 2004-05-21
ES2276134T3 (es) 2007-06-16
BR0315836A (pt) 2005-09-13
ZA200502701B (en) 2005-10-13
PT1560830E (pt) 2007-01-31
ATE343582T1 (de) 2006-11-15
US7589115B2 (en) 2009-09-15
MXPA05004480A (es) 2005-07-26
DE60309344D1 (de) 2006-12-07
RS20050327A (en) 2007-06-04
UA80160C2 (en) 2007-08-27
EA200500603A1 (ru) 2005-10-27
JP4366477B2 (ja) 2009-11-18
DK1560830T3 (da) 2007-02-26
CN1708500A (zh) 2005-12-14
CA2504219A1 (en) 2004-05-21
DE60309344T2 (de) 2007-02-08
TW200424204A (en) 2004-11-16
US20050054703A1 (en) 2005-03-10
JP2006508947A (ja) 2006-03-16
SI1560830T1 (sl) 2007-02-28
EP1560830B1 (en) 2006-10-25
MY136822A (en) 2008-11-28
US20050165027A1 (en) 2005-07-28
US20080090819A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
ECSP055823A (es) DERIVADOS DE [6,7-DIHIDRO-5H-IMIDAZO[1,2-a]IMIDAZOL-3-SULFONILAMINO]-PROPIONAMIDA
CR6577A (es) Inhibidores triciclicos de poli(adp-ribosa) polimerasas
ECSP045245A (es) N-aril-2-oxazolidinona-5-carboxamidas y sus derivados
DE60334016D1 (de) Antibakterielle mittel
ATE461217T1 (de) Glp-1-verbindungen
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
UY26380A1 (es) Inhibidores de fab i
ECSP045217A (es) Derivados de n-bifenilmetil aminocicloalcancarboxamida con un sustituyente en el metilo, util como antagonistas de bradicinina
BR0214309A (pt) Derivados aril-1,4-pirazina substituìdos
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
CR8302A (es) Compuestos heterociclicos fusionados
NO20044054L (no) Administrering av midler for behandling av betennelse
UY25677A1 (es) Nuevos agentes bacterianos de isoxazolinona
EA200501253A1 (ru) Производные пиразоло[1,5-a][1,3,5]триазина в качестве лигандов каннабиноидных рецепторов
ECSP055844A (es) Nuevos compuestos triciclicos
DE60331849D1 (de) Antibakterielle wirkstoffe
ECSP10010196A (es) Derivados de amidas del ácido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxílico
DE60303441D1 (en) N-biphenylmethylaminocycloalkancarboxamid-derivative
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
ATE326467T1 (de) Imidazo 1,2-aöpyridine
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
UY29532A1 (es) Derivados del ácido 6,7-dihidro-5h-imidazo(1,2-a)imidazol-3-sulfónico
IS7868A (is) Notkun á kortkólíberín-úrókortín kerfi í meðferð á bólguvaldandi sjúkdómum.
DE60307997D1 (de) Zusammensetzungen mit biostimulierender wirksamkeit

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160120